1. South Korea Stocks

  2. •

    Industrials

  3. •

    Conglomerates
SK Discovery Co., Ltd.

SK Discovery Co., Ltd.

006125.KS
SK Discovery Co., Ltd.KR flagKorea Exchange
37,700.00
KRW
-500.00
- -
1.02TMarket Cap
SK Discovery Co., Ltd.
006125.KS
(Korea Exchange)

Recent

price

37,700.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
900,728.39
1,017,876.32
1,034,937.94
986,888.74
724,797.8
532,675.58
461,294.61
567,055.86
386,571.13
246,233.82
221,672.87
325,529.47
441,145.6
453,851.79
473,906.47
546,991.95
602,071.63
Revenue per Share
30,926.03
17,649.05
9,014.2
-3,693.41
-2,496.64
5,615.78
7,160.74
63,451.21
3,942
8,846
13,096
10,478
21,631
9,699
1,912
6,961
13,701.03
Basic EPS, GAAP
1,274.99
-45,666.55
7,072.2
-23,906.99
-48,060.96
-75,743.64
-34,772.67
-29,893.63
-23,237.63
4,743.98
3,576.95
-32,939.4
-27,439.35
-18,797.76
-37,596.01
-9,793.01
-9,221.95
Free Cash Flow per Basic Share
2,922.16
1,791.52
1,621.94
1,747.85
1,428.44
1,360.16
1,708.42
2,434.42
1,737.64
1,416.42
1,338.68
1,727.09
2,896.64
3,602.76
3,421.73
3,767.44
1,231.1
Dividend per Share
68,639.78
134,051.56
138,801.72
141,551.31
113,292.79
123,428.83
112,002.11
167,990.2
108,469.45
106,526.17
119,261.12
128,812.71
150,278.82
158,831.39
164,153.45
172,607.55
186,618.33
Book Value per Share
159,462.2
176,183.23
184,944.19
202,027.77
162,995.64
224,378.25
197,747.51
161,738.67
113,757.07
108,013.43
122,341.01
143,344.66
256,754.8
268,746.32
296,992.62
323,264.87
336,383.3
Tangible Book Value per Share
9
9
9
8
10
10
12
11
18
20
20
20
20
20
19
19
18
Basic Weighted Avg Shares
7,944,225
8,864,967
9,160,085
8,256,550
7,283,608
5,269,176
5,322,182
6,415,901
6,939,172
5,021,068
4,519,464
6,614,328
8,717,115
8,939,217
9,039,603
10,164,014
11,047,142
Sales/Revenue/Turnover
2.25
2.6
2.08
2.35
2.05
2.28
3.56
1.28
1.44
3.46
3.83
1.12
4.16
2.87
1.91
3.56
3.99
Operating Margin (%)
88,617
62,554
72,553
79,500
85,154
103,074
110,910
127,617
59,589
106,742
114,428
116,090
180,515
346,288
367,750
522,213
536,609
Depreciation Expense
272,761
153,710
79,783
-30,900
-25,089
55,551
82,617
717,913
70,761
180,383
267,001
212,899
427,432
191,035
36,471
129,347
251,394
Net Income, GAAP
23.51
17.88
17.98
76.14
59.23
19.32
27.76
24.74
63.17
- -
31.13
25.35
0.93
29.4
32.71
23.89
29.54
Effective Tax Rate (%)
3.43
1.73
0.87
-0.37
-0.34
1.05
1.55
11.19
1.02
3.59
5.91
3.22
4.9
2.14
0.4
1.27
2.28
Profit Margin (%)
-168,941
171,308
711,668
583,590
518,067
986,459
374,379
624,590
75,236
330,192
1,002,127
824,166
2,043,155
2,182,404
1,699,650
1,722,337
2,139,046
Working Capital
310,508
608,350
1,192,261
1,245,017
1,794,543
2,402,497
1,324,631
1,076,266
505,758
895,085
1,387,902
1,588,274
2,047,384
2,873,198
4,113,337
4,988,660
5,274,343
LT Debt
1,355,929
1,620,429
1,738,212
1,783,544
2,006,100
2,585,779
2,662,430
2,143,595
2,318,569
2,323,215
2,616,362
3,069,308
5,953,322
6,069,572
6,503,023
6,851,246
7,037,129
Total Equity
5.98
6.12
4.38
1.19
1.4
1.82
2.43
1.28
0.92
- -
2.61
0.99
4.36
1.72
0.97
2.02
2.18
Return on Invested Capital (%)
16.73
5.28
1.46
-1.44
-0.92
1.47
0.41
13.1
1.31
- -
4.21
3.27
4.92
2.29
1.16
2.15
2.43
Return on Capital (%)
57.53
17.34
6.66
-2.56
-2.16
4.71
6.57
44.97
3.68
8.76
11.6
8.43
15.3
6.27
1.17
4.08
7.69
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2,396,790
2,307,542
2,726,481
LT Borrowings
3,384,707
3,873,079
4,184,839
LT Finance Leases
1,048,170
1,115,581
1,089,505
Preferred Equity and Hybrid Capital
6,792
6,792
6,792
Shares Outstanding
17
18
17
Market Capitalization
693,691
725,435
710,089

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
5,581,489
5,465,970
6,822,257
Cash, Cash Equivalents & STI
2,508,813
2,463,603
2,888,282
Accounts Receivable, Net
1,201,941
1,203,956
1,473,087
Inventories
1,177,920
1,302,337
1,270,593
Total Current Liabilities
3,733,664
3,743,633
4,683,210
Payables & Accruals
- -
- -
- -
ST Debt
2,396,790
2,307,542
2,726,481
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.02%
25.14%
5.35%
Free Cash Flow
-123.6%
-209.88%
-74.63%
Net Income, GAAP
112.94%
39.79%
254.66%
Sales/Revenue/Turnover
8.63%
18.85%
12.44%
Total Cash Common Dividend
20.15%
22.98%
7.26%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,158,527
2,119,448
2,189,579
2,572,049
9,039,603
2025
2,406,122
2,497,785
2,601,280
2,658,828
10,164,014
2026
3,289,250
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-506
638
1,920
- -
1,912
2025
2,610
910
714
- -
6,961
2026
9,206
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38.98
4,289.18
1,841.54
- -
3,421.73
2025
- -
- -
1,033.78
- -
3,767.44
2026
180.7
- -
- -
- -
- -
Similar Companies
Dalrada Financial Corporation (DFCO)
The Siam Cement Public Company Limited (SCVPF)
KPX Holdings Co.,Ltd. (092230.KS)
Alphax Food System Co., Ltd (3814.T)
Billion Electric Co., Ltd. (3027.TW)
Veritiv Corporation (VRTV)
Business
SK Discovery Co., Ltd. operates as a holding company overseeing subsidiaries in environmentally friendly materials, vaccines and pharmaceuticals, energy and chemicals, and real estate development primarily in South Korea and internationally. Founded in 1969 and headquartered in Seongnam-si, South Korea, the company holds stakes in key affiliates including SK chemicals, which provides green chemicals such as bio-materials, composites, high-performance materials, and energy-saving materials including PET resin and PETG resin; SK plasma and SK bioscience, which deliver healthcare solutions encompassing vaccines, plasma-derived products like albumin, tablets, patches, and treatments for diagnosis, prevention, and therapy; SK gas, which manages LPG storage, tank terminals, and power generation; and SK D&D, which develops commercial facilities, office buildings, hotels, urban and luxury housing, as well as renewable energy projects like solar and wind power. Geographically, operations span domestic markets with growing international reach through subsidiaries' exports and partnerships. In recent developments, SK chemicals targets a specialty strategy in 2025 with organizational restructuring around green materials and recycling businesses, product innovation in copolyesters, and customer expansion; SK Biopharmaceuticals, an affiliate, in-licenses a second radiopharmaceutical therapy candidate from Wisconsin Alumni Research Foundation in November 2025 following its 2024 asset and supply agreements for Actinium-225, while forming a joint venture Mentis Care with Eurofarma in October 2025 for AI-based epilepsy management.